Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication:: 7 vs. 14 day treatment

被引:12
作者
Bosques-Padilla, FJ
Garza-González, E
Calderón-Lozano, IE
Reed-SanRoman, G
de Ariño Suárez, M
Valdovinos-Díaz, MA
Orozco-Gámiz, A
Blancas-Valencia, JM
Tamayo-de la Cuesta, JL
机构
[1] Univ Autonoma Nuevo Leon, Hosp Univ Dr Jose Eleuterio Gonzalez, Serv Gastroenterol, Monterrey 64460, Nuevo Leon, Mexico
[2] Univ Autonoma Nuevo Leon, Fac Med, Dept Microbiol, Monterrey 64460, Nuevo Leon, Mexico
[3] Collaborat Grp Digest Dis Res, Mexico City, DF, Mexico
关键词
D O I
10.1111/j.1083-4389.2004.00265.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background. Because of the increasing resistance to clarithromycin and metronidazole, two of the antibiotics used for the eradication of Helicobacter pylori, new therapeutic alternatives are needed. The aim of this study was to determine the efficacy of a randomized, comparative trial of 7 vs. 14-day triple treatment with rabeprazole, ofloxacin and amoxicillin for H. pylori eradication. Material and Methods. The present authors studied 76 dyspeptic patients infected with H. pylori diagnosed by both histology and a rapid urease test. Patients were randomized to receive rabeprazole (20 mg b.i.d.), plus ofloxacin (400 mg b.i.d.) and amoxicillin (1000 mg b.i.d.) for 7 days (group 1) vs. 14 days (group 2) and were followed by 6 weeks. Eradication was assessed 4 weeks after completing the course of study treatment by the C-14-urea breath test. Per protocol and intention-to-treat eradication rates were determined. Results. For the intention to treat analysis, the eradication rate was 62.2% for group 1 and 92.3% for group 2 (p = .004). For the per protocol analysis, eradication rate for group 1 was 63.9% and for group 2 was 97.3% (p = .001). Conclusions. Triple therapy with rabeprazole, amoxicillin and ofloxacin by 14 days was efficient for H. pylori eradication and therefore deserves further study. The same regimen prescribed for 7 days had a significantly lower and unacceptable cure rate and should not be used.
引用
收藏
页码:417 / 421
页数:5
相关论文
共 16 条
[11]   Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment:: a randomized trial [J].
Nista, EC ;
Candelli, M ;
Cremonini, F ;
Cazzato, IA ;
Di Caro, S ;
Gabrielli, M ;
Santarelli, L ;
Zocco, MA ;
Ojetti, V ;
Carloni, E ;
Cammarota, G ;
Gasbarrini, G ;
Gasbarrini, A .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (06) :627-633
[12]  
Perri F, 2001, AM J GASTROENTEROL, V96, P58
[13]   Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy' [J].
Perri, F ;
Festa, V ;
Merla, A ;
Barberani, F ;
Pilotto, A ;
Andriulli, A .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (08) :815-820
[14]   Treatment of Helicobacter pylori infection [J].
Perri, F ;
Qasim, A ;
Marras, L ;
O'Morain, C .
HELICOBACTER, 2003, 8 :53-60
[15]   Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori [J].
Pipkin, GA ;
Williamson, R ;
Wood, JR .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1998, 12 (09) :823-837
[16]   Review article:: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies [J].
van Oijen, AHAM ;
Verbeek, AL ;
Jansen, JBMJ ;
de Boer, WA .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (08) :991-999